Loading...
•
Sep 30, 2025
Prime Medicine Q3 2025 Earnings Report
Prime Medicine reported its Q3 2025 financial results, showing continued R&D investments and a narrowed net loss compared to the same period last year.
Key Takeaways
Prime Medicine's Q3 2025 performance reflected steady pipeline advancement and disciplined expense management, though the company remains in a net loss position as it progresses its preclinical and early-stage programs.
Reported total revenue of $1.23 million, primarily from collaboration income
Net loss narrowed to $50.6 million from $52.5 million in Q3 2024
R&D expenses increased to $44.0 million, driven by IP and facility costs
Cash, cash equivalents, and investments stood at $213.3 million, expected to fund operations into 2027
Revenue by Segment
Forward Guidance
Prime Medicine expects its cash position of $213.3 million as of Q3 2025 to support operations into 2027 as it advances key programs including WD, AATD, and CF.
Positive Outlook
- Cash runway expected to fund operations into 2027
- On track to file INDs for WD and AATD programs in 2026
- Initial clinical data for WD and AATD expected in 2027
- Recent nomination of PM647 strengthens pipeline
- Strategic focus on liver-targeted programs shows continued momentum
Challenges Ahead
- Company remains in a net loss position
- G&A and R&D expenses remain high despite reductions
- No near-term revenue-generating products
- IND filings still pending for major pipeline programs
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...